Candice Yong

发表

A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective.

D. Fisher, Shu-chuen Li, G. Sklar, 2009, International journal of antimicrobial agents.

C. Mullins, B. Seal, A. Hussain, 2014, Journal of geriatric oncology.

C. Plaisant, J. Ciezki, C. Reddy, 2017, PloS one.

ASSOCIATION OF COMMUNITY CANCER CENTERS IMPROVING CARE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESULTS FROM A NATIONAL QUALITY SURVEY FOR THORACIC SURGEONS, RADIATION ONCOLOGISTS, AND MEDICAL ONCOLOGISTS

B. Stiles, Percy Lee, L. Boehmer, 2021 .

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.

R. Mehra, Yiduo Zhang, B. Seal, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare.

C. Mullins, B. Seal, A. Hussain, 2012 .

Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer

C. Mullins, E. Onukwugha, C. Yong, 2014, Current opinion in oncology.

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis

P. Hari, D. Faller, C. Asche, 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer

Eberechukwu Onukwugha, C. Mullins, B. Seal, 2014, BMC Medical Research Methodology.

Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer

M. Kelley, B. Seal, K. Lee, 2021, BMC cancer.

Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

S. Ramsey, Yiduo Zhang, B. Seal, 2019, BMC Cancer.

Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer

C. Mullins, A. Hussain, E. Onukwugha, 2018, PloS one.

Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer

Eberechukwu Onukwugha, C. D. Mullins, C. Mullins, 2013 .

The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies.

P. Hari, V. Morrison, M. Blazer, 2017, Journal of geriatric oncology.

The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis.

C. Mullins, B. Seal, A. Hussain, 2014, Journal of geriatric oncology.

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy

S. Noga, K. Shermock, D. Merola, 2018, Journal of managed care & specialty pharmacy.

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data

E. Onukwugha, J. Slejko, C. Yong, 2019, Cancer medicine.

Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method

B. Bolinder, K. Batt, K. Bognar, 2022, MDM policy & practice.

Use of and spending on supportive care medications among Medicare beneficiaries with cancer

B. Stuart, T. Shaffer, I. Zuckerman, 2014, Supportive Care in Cancer.

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis

P. Hari, D. Faller, C. Asche, 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.

N. Robert, B. Seal, Juliet Ndukum, 2021, Journal of Clinical Oncology.

Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.

N. Robert, Juliet Ndukum, D. Waterhouse, 2023, Future oncology.

Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment

R. Mehra, B. Seal, I. Cotarla, 2022, Patient preference and adherence.